Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Billion-dollar Biogen deal gives Denali fuel to validate CNS delivery platform

Denali to advance lead Parkinson’s program, BBB-penetrant candidates with cash infusion from Biogen

Virginia Li, Associate Editor
August 7, 2020 1:29 AM UTC
Updated on Aug 8, 2020 at 1:44 AM UTC

With more than $1 billion in upfront money via its biggest deal yet, Denali now has enough firepower to bring its lead program into late-stage testing and validate its CNS delivery technology in the clinic.

The deal with Biogen Inc. (NASDAQ:BIIB) also helps Denali Therapeutics Inc. (NASDAQ:DNLI) derive value from its Transport Vehicle (TV) technology in areas where it wasn’t planning to invest. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

Denali Therapeutics Inc.